• 1
    Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008; 58: 1525.
  • 2
    Geirsson AJ, Steinsson K, Guthmundsson S, Sigurthsson V. Systemic sclerosis in Iceland: a nationwide epidemiological study. Ann Rheum Dis 1994; 53: 5025.
  • 3
    Silman A, Jannini S, Symmons D, Bacon P. An epidemiological study of scleroderma in the West Midlands. Br J Rheumatol 1988; 27: 28690.
  • 4
    Maricq HR, Weinrich MC, Keil JE, Smith EA, Harper FE, Nussbaum AI, et al. Prevalence of scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum 1989; 32: 9981006.
  • 5
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 58190.
  • 6
    Leroy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 2025.
  • 7
    Valentini G, Della Rossa A, Bombardieri S, Bencivelli W, Silman AJ, D'Angelo S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001; 60: 5928.
  • 8
    Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 2003; 49: 15663.
  • 9
    Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 47383.
  • 10
    Clarke AE, Zowall H, Levinton C, Assimakopoulos H, Sibley JT, Haga M, et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol 1997; 24: 105160.
  • 11
    Bernatsky S, Duffy C, Malleson P, Feldman DE, St. Pierre Y, Clarke AE. Economic impact of juvenile idiopathic arthritis. Arthritis Rheum 2007; 57: 448.
  • 12
    Bernatsky S, Dobkin PL, De Civita M, Penrod JR. Co-morbidity and physician use in fibromyalgia. Swiss Med Wkly 2005; 135: 7681.
  • 13
    Penrod JR, Bernatsky S, Adam V, Baron M, Dayan N, Dobkin PL. Health services costs and their determinants in women with fibromyalgia. J Rheumatol 2004; 31: 13918.
  • 14
    Schedule of benefits: physician services under the Health Insurance Act, 2005. Toronto (Ontario): Queen's Printer; 2005.
  • 15
    Canadian Institute of Health Information. DAD resource indicators. Ottawa: Canadian Institute of Health Information; 1997.
  • 16
    Ontario Case Cost Project (OCCP). Ontario guide to case costing, version 1.1. Ottawa: OCCP; 1995.
  • 17
    Statistics Canada. Comparable health indicators: Canada, provinces, and territories. Ottawa: Statistics Canada; 2004.
  • 18
    Statistics Canada. Hospital indicators, 1993–1994. Ottawa: Statistics Canada; 1996.
  • 19
    Statistics Canada. Statistics Canada's 1998 General Social Survey: overview of the time use of Canadians in 1998. Ottawa: Statistics Canada; 1998.
  • 20
    Gold MR. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 1996.
  • 21
    Statistics Canada. Canadian Economic Observer June 1992. Ottawa: Statistics Canada; 1992.
  • 22
    Statistics Canada. Households' unpaid work: measurement and evaluation. Ottawa: Statistics Canada; 1995.
  • 23
    Callaghan R, Prabu A, Allan RB, Clarke AE, Sutcliffe N, St Pierre Y, et al. Direct healthcare costs and predictors of costs in patients with primary Sjogren's syndrome. Rheumatology (Oxford) 2007; 46: 10511.
  • 24
    Ritzwoller DP, Crounse L, Shetterly S, Rublee D. The association of comorbidities, utilization and costs for patients identified with low back pain. BMC Musculoskelet Dis 2006; 7: 72.
  • 25
    Belotti Masserini A, Zeni S, Cossutta R, Soldi A, Fantini F. Cost-of-illness in systemic sclerosis: a retrospective study of an Italian cohort of 106 patients. Reumatismo 2003; 55: 24555. In Italian.
  • 26
    Clarke AE, Penrod J, St Pierre Y, Petri MA, Manzi S, Isenberg DA, et al. Underestimating the value of women: assessing the indirect costs of women with systemic lupus erythematosus. J Rheumatol 2000; 27: 2597604.
  • 27
    Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999; 26: 215967.
  • 28
    Pope JE, Lee P, Baron M, Dunne J, Smith D, Docherty PS, et al. Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. J Rheumatol 2005; 32: 12738.
  • 29
    McNearney TA, Reveille JD, Fischbach M, Friedman AW, Lisse JR, Goel N, et al. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum 2007; 57: 31826.
  • 30
    Wilson L. Cost-of-illness of scleroderma: the case for rare diseases. Semin Arthritis Rheum 1997; 27: 7384.
  • 31
    Maetzel A, Li LC, Pencharz J, Tomlinson G, Bombardier C. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis 2004; 63: 395401.